Older adults receiving the GLP-1 agonist semaglutide showed less worsening in a protein-based dementia forecast than those receiving placebo.
“These additional targets offer possible ways for semaglutide to influence the protein pattern beyond the effects of eating less and losing weight. A blood-protein score may help track how a treatment changes biology associated with dementia, not just estimate future risk.”